HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder Cites Overseas Growth As Key To Building Business Through 2010

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder's international operations are central to a three-year business-building initiative expected to fuel annual sales growth of 6 percent to 8 percent, the firm reported during its March 6 Analyst and Investor Day in New York

You may also be interested in...



Half-Way Into Lauder’s Strategic Plan, Targeted Prestige Driving Success

The Estee Lauder Companies is well on its way to fulfilling goals of a four-year strategy unveiled in 2009, crediting strong performances in emerging markets and growth of its prestige beauty brands.

Estee Lauder Uncloaks Four-Year Plan For Slashing Costs, Growing Core Biz

The Estee Lauder Companies is implementing a four-year strategy to optimize its core strengths and cut costs by up to $550 million, the firm announced Feb. 5 in tandem with second-quarter sales, which declined 6 percent compared with the prior year, excluding the impact of foreign exchange

Estee Lauder Uncloaks Four-Year Plan For Slashing Costs, Growing Core Biz

The Estee Lauder Companies is implementing a four-year strategy to optimize its core strengths and cut costs by up to $550 million, the firm announced Feb. 5 in tandem with second-quarter sales, which declined 6 percent compared with the prior year, excluding the impact of foreign exchange

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel